Zhang, Mengwen
Pan, Xingyi
Fujiwara, Kenji
Jurcak, Noelle
Muth, Stephen
Zhou, Jiaojiao http://orcid.org/0000-0003-0442-6183
Xiao, Qian
Li, Anqi
Che, Xu
Li, Zihai
Zheng, Lei
Article History
Received: 26 May 2021
Revised: 11 September 2021
Accepted: 15 September 2021
First Online: 29 October 2021
Competing interests
: L.Z. receives grant support from Bristol-Meyer Squibb, Merck, Astrazeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. L.Z. is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, Datarevive, QED, Xilio, Natera, Novagenesis, Snow Lake, and Mingruizhiyao. L.Z. holds shares at Alphamab and Mingruizhiyao. Z.H.L. has received sponsored research agreement from Bristol-Meyer Squibb and Heat Biologics, and is a paid consultant for Alphamab, Hengenix Biotech, and Heat Biologics. He held a patent on targeting GARP for diagnosis and treatment of cancer (WO2017173091A1).